Prostate-specific antigen 1.5-4.0 ng/mL: A diagnostic challenge and danger zone

BJU International

Volumn 108, Issue 11, 2011, Pages 1743-1749

  Crawford, E David ^a   Moul, Judd W ^b   Rove, Kyle O ^a   Pettaway, Curtis A ^c   Lamerato, Lois E ^d   Hughes, Alexa ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b DUKE UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d HENRY FORD HOSPITAL   (United States)

Author keywords

benign prostatic hyperplasia; digital rectal examination; prostate cancer; prostate specific antigen; screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AFRICAN AMERICAN; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; DIAGNOSTIC VALUE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; REFERENCE VALUE; RETROSPECTIVE STUDY; RISK FACTOR; UNITED STATES;

AFRICAN AMERICANS; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REFERENCE VALUES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 81255158339     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10224.x     Document Type: Article

References (30)

1. Wang MC, Valenzuela LA, Murphy GP, et al,. Purification of a human prostate specific antigen. Invest Urol 1979; 17: 159-63 (Pubitemid 10132507)
2. Ferro MA, Barnes I, Roberts JBM, et al,. Tumour markers in prostatic carcinoma: a comparison of prostate-specific antigen with acid phosphatase. Br J Urol 1987; 60: 69-73 (Pubitemid 17089205)
3. Catalona WJ, Smith DS, Ratliff TL, et al,. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156-61
4. Brawer MK, Chetner MP, Beatie J, et al,. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992; 147: 841-5
5. Kuriyama M, Wang MC, Papsidero LD, et al,. Quantitation of prostate specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res 1980; 40: 4658-62 (Pubitemid 11199734)
6. Seamonds B, Yang N, Anderson K, et al,. Evaluation of prostate-specific antigen and prostatic acid phosphatase as for prostate cancer markers. Urology 1986; 28: 472-9 (Pubitemid 17063361)
7. Kuriyama M, Wang MC, Lee CL, et al,. Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens. J Natl Cancer Inst 1982; 68: 99-105 (Pubitemid 12167070)
8. Cooner WH, Mosley BR, Rutherford CL Jr, et al,. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 1990; 143: 1146-52
9. Thompson IM, Pauler DK, Goodman PJ, et al,. Prevalence of prostate cancer among men with a prostate-specific antigen level 4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-46
10. Mochtar CA, Kiemeney LALM, van Riemsdijk MM, et al,. Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia. Eur Urol 2003; 44: 695-700 (Pubitemid 37542928)
11. Schroder FH, van der Cruijsen-Koeter I, de Koning HJ, et al,. Prostate cancer detection at low prostate specific antigen. J Urol 2000; 163: 806-12 (Pubitemid 30091621)
12. Thompson IM, Pauler DK, Goodman PJ, et al,. Prevalence of prostate cancer among men with a prostate-specific antigen level 4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-46
13. Tang P, Sun L, Uhlman MA, et al,. Initial prostate specific antigen 1.5 ng/mL or greater in men 50 years old or younger predicts higher prostate cancer risk. J Urol 2010; 183: 946-51
14. Krumholtz JS, Carvalhal GF, Ramos CG, et al,. Prostate-specific antigen cut off of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. Urology 2002; 60: 469-74
15. Hughes A, O'Donnell C, Tandberg DJ, Crawford ED,. Use of a 1.5 PSA threshold to identify increased risk for prostate cancer in a screening population. Abstract presented at American Urological Association Annual Meeting, San Francisco, 29 May to 3 June, 2010
16. Schroder FH, Raaijmakers R, Postma R, et al,. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. J Urol 2005; 174: 489-94; discussion 493-4
17. Van der Cruijsen-Koeter IW, Roobol MJ, Wildhagen MF, et al,. Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial ERSPC Rotterdam. Urology 2006; 68: 615-20 (Pubitemid 44436477)
18. Ekwueme DU, Stroud LA, Chen Y,. Cost analysis of screening for, diagnosing, and staging prostate cancer based on a systematic review of published studies. Prevent Chronic Dis 2007; 4: 1-17
19. Crawford ED, Pinsky PF, Chia D, et al,. Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial. J Urol 2006; 175: 1286-90; discussion 1290
20. Crawford ED, Wilson SS, McConnell JD, et al,. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 2006; 175: 1422-6
21. Marberger MJ, Andersen JT, Nickel JC, et al,. Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials. Eur Urol 2000; 38: 563-8
22. Roehrborn CG, Boyle P, Bergner D, et al,. Serum prostate-specific antigen and prostate volume predicts long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology 1999; 54: 662-9 (Pubitemid 29449427)
23. Bartsch G, Fitzpatrick JM, Schalken JA, et al,. Consensus statement: the role of prostate-specific antigen in managing the patient with benign prostatic hyperplasia. BJU Int 2004; 93 (Suppl. 1): 27-9 (Pubitemid 38373078)
24. Crawford ED, Tandberg DJ, Sullivan KF, et al,. Medical therapy use among men at increased risk of BPH progression based on the PSA threshold of 1.5 ng/mL or greater: an analysis of data from the Prostate Cancer Awareness Week screening program. Abstract presented at American Urological Association Annual Meeting, Chicago, April 25-30, 2009
25. Punglia RS, D'Amico AV, Catalona WJ, et al,. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 2003; 349: 335-42 (Pubitemid 36886239)
26. Wilson SS, Crawford ED,. Screening for prostate cancer. Clin Prostate Cancer 2004; 3: 21-5. Review (Pubitemid 39006582)
27. Hakama M, Stenman UH, Aromaa A, et al,. Validity of the prostate specific antigen test for prostate cancer screening: a followup study with a bank of 21,000 sera in Finland. J Urol 2001; 166: 2189-91 (Pubitemid 33065254)
28. Gann PH, Hennekens CH, Stampfer MJ,. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995; 273: 289-94
29. Carter HB, Ferrucci L, Kettermann A, et al,. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006; 98: 1521-7 (Pubitemid 44680903)
30. Lilja H, Ulmert D, Björk T, et al,. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol 2007; 25: 431-6 (Pubitemid 350002992)